Pharmacokinetics and safety of multiple oral doses of sustained-release 4- aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 1 Keith C Hayes, PhD, Patrick J Potter, MD, Jane T Hsieh, MSc, Mitchell A Katz, PhD, Andrew R Blight, PhD, Ron Cohen, MD Archives of Physical Medicine and Rehabilitation Volume 85, Issue 1, Pages 29-34 (January 2004) DOI: 10.1016/S0003-9993(03)00651-8
Fig 1 Mean plasma concentrations by time and dosage level for the 11 subjects completing the study. Abbreviation: bid, twice daily. Archives of Physical Medicine and Rehabilitation 2004 85, 29-34DOI: (10.1016/S0003-9993(03)00651-8)
Fig 2 Mean Cmax and AUC0–12 versus Fampridine-SR dosage level for the 11 subjects completing the study. Vertical bars represent ±standard deviation. Archives of Physical Medicine and Rehabilitation 2004 85, 29-34DOI: (10.1016/S0003-9993(03)00651-8)